Stock market today: S&P 500 falls as government shutdown, trade jitters persist
Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology company with a market capitalization of $21.31 billion and strong financial health according to InvestingPro analysis, announced Tuesday that it expects to record approximately $2 million in acquired in-process research and development, upfront and milestone expenses on a pre-tax basis for the third quarter of 2025. According to a press release statement, this estimated charge is anticipated to reduce GAAP and non-GAAP net income per diluted share by about $0.01 for the period. The company maintains robust liquidity with current assets more than doubling its short-term obligations.
The company began presenting acquired in-process research and development, upfront and milestone expenses as a separate line item in its condensed consolidated statements of income starting in the first quarter of 2025. These expenses include costs related to collaboration and license agreements, such as upfront and milestone payments, and, when applicable, premiums on equity securities and asset acquisitions of in-process research and development. Biogen stated that it does not forecast such expenses due to the uncertainty regarding the timing and magnitude of these transactions.
Biogen also noted that its results for the quarter ended September 30, 2025, have not been finalized and remain subject to financial statement closing procedures. The company stated that there can be no assurance that the final results will not differ from the preliminary unaudited estimates provided.
This information is based on a statement included in Biogen’s Form 8-K filed with the Securities and Exchange Commission.
In other recent news, Biogen has been in the spotlight with several notable developments. RBC Capital has adjusted its price target for Biogen, lowering it slightly from $219 to $217, while maintaining an Outperform rating. The firm anticipates that Biogen might exceed consensus estimates in its upcoming earnings report, projecting revenue of $2,493 million and earnings per share of $4.43. Additionally, Biogen, in collaboration with Eisai Co., Ltd., has announced the availability of Leqembi Iqlik, a subcutaneous injection for Alzheimer’s patients, in the U.S. This injection serves as a maintenance dosing option for those with mild cognitive impairment or mild dementia.
Jefferies has initiated coverage on Biogen with a Buy rating and a $190 price target, highlighting the low market expectations and potential for positive developments. Meanwhile, the FDA has issued a Complete Response Letter for Biogen’s high-dose SMA drug, requesting updates to technical information but finding no deficiencies in the clinical data. Furthermore, Biogen’s board member, Jesús Mantas, recently retired from IBM, has joined the board of the National Association of Corporate Directors. These developments underscore a period of activity and change for Biogen, with potential implications for its future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.